Anti-cancer Activity of Plant-produced Hpv16 E7 Vaccine.
From: ENEA, Italian National Agency for New Technologies, Energy and the Environment, BAS BIOTEC GEN, C.R. Casaccia, Via Anguillarese 301, 00123 Rome, Italy.
Vaccine
- Publish Date: Apr 2007
- ISSN: 0264-410X
- Volume: 25
- Issue: 16
- Pages: 3018-21
- Medium: Print
- Language: English
- Citation (JAMA): Massa Silvia, Franconi Rosella, Brandi Rossella, et al. Anti-cancer Activity of Plant-produced Hpv16 E7 Vaccine.. Vaccine Apr 2007;25:3018-21
Abstract
The E7 oncoprotein from Human Papilloma Virus (HPV) is an attractive candidate for anti-cancer vaccine development. In this study, we engineered HPV16 E7 coding sequence (wild type or mutagenized sequence, E7GGG) as fusions to beta-1,3-1,4-glucanase (LicKM) of Clostridium thermocellum and produced in Nicotiana benthamiana plants using a transient expression system. Target antigens were purified and evaluated in mice for their potential as prophylactic and therapeutic vaccine candidates. Both fusion proteins induced E7-specific IgG and cytotoxic T-cell responses and protected mice against challenge with E7-expressing tumor cells. Furthermore, when administered after challenge, these plant-produced antigens prevented tumor development.
Mesh Headings (Keywords): Animals, Cancer Vaccines, Mice, Mice, Inbred C57BL, Neoplasms, Experimental, Oncogene Proteins, Viral, Papillomaviridae, Recombinant Fusion Proteins, Tobacco, Viral Vaccines
Check for Full Text / PubMed Unique Identifier (PMID): 17280752
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.